Physicochemical Properties
| Molecular Formula | C11H18BRCLN2 |
| Molecular Weight | 293.631021022797 |
| Exact Mass | 328.01 |
| CAS # | 2243506-33-2 |
| PubChem CID | 138040845 |
| Appearance | White to yellow solid powder |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 16 |
| Complexity | 152 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C(C1C=CC=C(Br)C=1)N(CC)CCN.Cl |
| InChi Key | AQDSZKTVQVSVNC-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C11H17BrN2.2ClH/c1-2-14(7-6-13)9-10-4-3-5-11(12)8-10;;/h3-5,8H,2,6-7,9,13H2,1H3;2*1H |
| Chemical Name | N'-[(3-bromophenyl)methyl]-N'-ethylethane-1,2-diamine;dihydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | NMDAR/TRPM4-IN-2 (compound 8) (0-10 μM) decreases the interactions of GluN2A and GluN2B with TRPM4 in a dose-dependent manner[1]. NMDAR/TRPM4-IN-2 removes the CREB shutdown pathway and restores ERK1/2 activation and IEG induction while sparing the synaptic activity-driven, transcription-promoting functions of NMDARs[1]. |
| References |
[1]. Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants. Science. 2020 Oct 9;370(6513):eaay3302. |
Solubility Data
| Solubility (In Vitro) |
DMSO: 250 mg/mL (757.37 mM) H2O: 100 mg/mL (302.95 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4056 mL | 17.0282 mL | 34.0565 mL | |
| 5 mM | 0.6811 mL | 3.4056 mL | 6.8113 mL | |
| 10 mM | 0.3406 mL | 1.7028 mL | 3.4056 mL |